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ABSTRACT 
In the present research programme, Verapamil Hydrochloride loaded Sodium Alginate/Polyethylene oxide/Montmorillonite nanocomposite 
beads were prepared by using gelation method.   Sodium alginate (SA) and  Poly ethylene oxide (PEO) with different ratios were blended with 
different weight ratios of MMT solution. The nanocomposite beads were characterized Fourier Transform Infrared Spectroscopy (FTIR), 
Scanning Electron Microscope (SEM), X-ray diffraction (X-RD). FTIR was used to understand the hydrogen bonding between SA, PEO, MMT and 
drug. The X-RD studies were performed to understand the crystalline nature of drug after encapsulation into the beads. SEM was used to study 
the surface morphology of nanocomposite beads. In vitro studies were carried out in buffer media by using UV-vis spectroscopy(λmax-263nm) at 
pH 7.4. The Controlled drug release studies were observed upto 12hrs.  
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In recent years, researcher’s shows much interest in the 
preparation of Nanocomposite materials for biomedical 
applications. Nanocomposites are composite materials in 
which at least one phase shows dimensions in the nanometer 
range. These nano-materials exhibit unique properties for 
which they are considered as the materials of the 21st 
century. The nanocomposite materials are of great 
importance for many industries because major 
improvements in functional and structural properties in 
material applications. The growing demand for 
nanocomposite material shows a promising future. The 
application of such material is strongly influencing the 
industry of medicine and pharmacy 1. 
The site specific drug delivery provides an opportunity for 
optimum pharmacological activity of drug. Recently special 
attentions have been paid to find novel approaches to control 
the rate of drug release by means of carrier systems, where 
the drug should be dispersed in an inert matrix. Polymer 
based nanocomposites are of great importance as controlled 
drug delivery vehicles due to their unique structures and 
properties. These nanocomposites are prepared using 
inorganic materials including Montmorillonite (MMT), 
Hydroxyapatite (HA), calcium deficient hydroxyapatite2,3, 
mineral clays4-8, and silica9. They possess improved 
mechanical properties, swelling properties, drug loading 
efficiency and controlled release behaviour as compared to 
bulk counterparts. Clay minerals (layered silicates) have 
been proposed as fundamental constituents of several MDDS, 
with different purposes and acting through various 
mechanisms3. The intercalation of organic species into 
layered inorganic materials provides a useful and convenient 
route to prepare organic-inorganic hybrids that combine the 
properties of both inorganic host and organic guest 4,5. A very 
interesting possibility is to use clay mineral polymer 
composites to modify drug release. Although clay minerals 
and polymers are frequently used as single drug carriers, this 
type of drug delivery system (DDS) often does not meet all 
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requirements. Preparation of polymer layered silicate 
composite offers the possibility of improving the single 
components properties: those of the clay mineral particles 
(stability of the clay mineral dispersions and changes in its 
ion exchange behavior) and, more frequently, those of the 
polymer (mechanical properties, swelling capacity, film 
forming abilities, rheological properties, bioadhesion or 
cellular uptake)6.  
Montmorillonite clay (MMT) belongs to the smectite group, 
composed of silica tetrahedral sheets layered between 
alumina octahedral sheets at a ratio of 2:1, respectively10. It 
has large specific surface area, exhibits good adsorbance 
ability, high cation exchange capacity, standout 
adhesiveness, and drug-carrying capability. Thus, MMT is a 
common ingredient in pharmaceutical products, both as 
excipient and as active support. It was reported 11 that drug 
incorporation into clays takes place by adsorption, both by 
intercalation into the clay structure within the interlayer 
spacing (by replacing the water molecules), and also on the 
surface. The most important interactions taking place 
between the two components of the hybrid system are 
ionic12. The ionic exchange process may take place by mixing 
ion exchangers with ionic drugs in solution. In biological 
fluids, “counterions” can displace the drug from the substrate 
and deliver it into the body, while the exchanger is 
eliminated. The positively charged edges on the layers of 
MMT can interact with anionic polymer like alginate (sodium 
salt of alginic acid) to form unique polymer silicate materials, 
having superior capability to incorporate drug molecules. 
Involvement of MMT to alginate composites decreases the 
drug release rate by increasing drug/matrix adsorbtion 
capacity/entrapment efficiency      
Sodium alginate contains pendant carboxylate and is known 
as polyanionic copolymer of 1,4 linked-α-L-guluronic acid 
and β-D-mannuronic acid residues found in brown 
seaweeds13. Physical cross-linking of sodium alginate could 
be done through electrostatic interactions between 
polyvalent cations especially Ca2+ and aligned guluronic 
blocks of alginate chains.13 Biocompatible polymers such as 
polyvinyl alcohol,14 chitosan,15 hdroxypropyl 
methylcellulose,16 and starch17 have been incorporated in the 
synthesis of alginate beads with improved properties and 
evaluated in the drug delivery and biomedical systems. In 
addition to biopolymers, inorganic and organic nanoparticles 
including silica,18 clay,19 carbon nanotubes,20 magnetic 
Fe3O4,21 and hydroxyapatite 22 have been used for the 
synthesis of alginate composite beads with unique structure 
and properties.   
Polyethylene oxide (PEO) is a nontoxic and water-soluble 
polymer, widely used in chemical, cosmetic, and 
pharmaceutical industries. PEO gels produced in water can 
be dehydrated and the material produced is extremely 
hydrophilic and possesses a good bioadhesive property23 . 
Due to its properties Polyethylene oxide (PEO) is used in 
various drug delivery systems. Christine et.al.,24 have 
reported PEO blend copolymer micelles as a delivery vehicle 
for dihydrotestosterone. Zeng et.al.,25 have also reported PEO 
blend nanoparticles with crosslinked cores as drug carrier. 
Polyethylene oxide (PEO) is a good drug delivery vehicle in 
pharmaceutical industries 26-27.  
In this research work the drug was used Verapamil 
Hydrochloride. Verapamil hydrochloride is a calcium channel 
blocker (acts on L‑type calcium channels in the heart causes 
a reduction in ionotropy and chronotropy, thus reducing 
heart rate and blood pressure). Approximately about 90% of 
verapamil is absorbed from GIT, but is subjected to very 
considerable first‑pass metabolism in the liver and the 
bioavailability is only about 20%. Verapamil exhibits 
bi‑or‑tri‑phasic6 elimination kinetics and is reported to have 
a terminal plasma half‑life of 2 to 8 hrs following a single oral 
dose or after intravenous administration. After repeated oral 
doses this increases to 4.5 to12 hrs. It acts within 5 mins of 
intravenous administration and in 1 to 2 hrs after an oral 
dose. The short biological half-life and poor availability of 
drug favor development of drug favor development of 
controlled release formulations 28-30. 
 
Recently some of the groups are working on clay loaded 
polymeric matrices for controlled release of drug delivery. 
Earlier Babul Reddy et.al.,31 have been prepared 5-flurouracil 
loaded chitosan-PVA/Na+MMT nanocomposite film for drug 
delivery and antibacterial studies. Rehab Abdeen et. al.,32 
have prepared modified chitosan-clay nanocomposite as a 
drug delivery system intercalation and in vitro release of 
ibuprofen. Ilescu et. al.,21 have been prepared 
montmorillonite nanocomposite as a drug delivery system-
incorporation and in vitro release of irinotecan.    
 
The scope of the present study was to synthesize, evaluation 
and drug delivery of sodium alginate/PEO/MMT 
nanocomposite beads using verapamil hydrochloride as a 
model drug. However, no report is available in the literature. 
The nanocomposite materials were characterized by Fourier 
infrared spectroscopy ( FTIR), X-ray diffraction (X-RD), 
scanning electron microscopy (SEM). The invitro release 
studies were carried out in buffer media at pH 7.4 by using 
UV-vis spectroscopy (λmax=263nm) and the results are 
presented here. The schematic representation as shown in 
Figure 1. 
MATERIALS AND METHODS 
Materials 
SA (viscosity [2 W/V%], 1100–1900 cps) was purchased 
from Merck, Mumbai, India, PEO (MW _70,000)  of analar 
grade purchased from Sd.Fine, Mumbai, India. Verapamil 
Hydrochloride (VPHCl) drug was purchased from Sigma-
Aldrich (St. Louise, USA). Montmorillonite clay (MMT) was 
supplied as powder by Southern Clay products, Inc. (Texas, 
USA) and CaCl2  from Fischer Scientific. All the chemicals and 
reagents were used without further purification. Double 
distilled water was used for preparation of all solutions. 
Procedure  
The nanocomposite beads of sodium alginate/polyethylene 
oxide/montmorillonite were prepared by gelation method. 
The sodium alginate and polyehylene oxide stock solutions 
were prepared 2 %(W/V).The solutions are mixed in 
different ratios as per given in the Table-1. To these solution 
different concentrations of VPHCl drug and Montmorillonite 
clay (MMT) are added at 70oC for 30mins to get homogenous 
solution. Afterwards the prepared slurry was put into 10 ml 
disposable syringe with the nozzle diameter of 3mm and 
added dropwise in 5 % of CaCl2 solution with continuous 
stirring at 300rpm. The obtained beads were left in the CaCl2 
solution overnight with constant stirring followed by wash with 
distilled water. The prepared SA/PEO/MMT nanocomposites 
beads were then dried in an oven at 50OC and stored in clean 
vials for further use. 
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% of EE 
SPM1 100 00 00 50 64.23 
SPM 2 70 30 00 50 62.81 
SPM 3 70 30 40 50 69.42 
SPM 4 70 30 40 70 73.35 
SPM 5 70 30 40 90 76.17 
SPM 6 70 30 60 50 71.53 
SPM 7 70 30 80 50 74.82 
SPM 8 60 40 40 50 59.61 
SPM 9 50 50 40 50 57.25 
 
 
Figure 1: A simple scheme for synthesis of Nanocomposite beads 
 
Encapsulation Efficiency: 
The % of encapsulation efficiency was estimated was 
calculated by using the following formula. 10 mg of 
nanocomposites beads were soaked and shaken occasionally 
in 100 ml of phosphate buffer solution pH.7.4 for 24h and 
then crushed the beads to ensure the complete extraction of 
VPHCl from beads. The VPHCl content was determined using 
a UV-Vis spectrophotometer (LabIndia, Mumbai, India) at 
the λmax of 263 nm with pH 7.4 PB solution as a blank. The 
average of three determinations was considered. The % 
encapsulation efficiency was calculated by the following 
equation (1)& (2): 
Drug loading (%) = 
                                     
                             
 X 100  
Encapsulation Efficiency EE (%) = 
                   
                       
 X 100 
In vitro drug release studies 
In vitro drug release studies of different formulations were 
performed at 37oC using a dissolution tester (Lab India, 
Mumbai, India) capable of eight baskets. Accurate quantity 
of nanocomposite beads (100mg) was immersed into 600mL 
of phosphate buffer solution pH7.4 at a rotation speed of 50 
rpm. At regular intervals of time, aliquot samples were 
withdrawn, and analyzed using UV spectrophotometer at 
fixed λ-max value of 263nm for verapamil hydrochloride, 
and the released drug amount was calculated by using 
concentration versus absorbance calibration curve. 
Characterization Methods  
Fourier Transform Infrared (FTIR) Spectral Analysis 
Brucker, Model: ALPHA II  (Make: Jarmany) Fourier 
Transform Infrared (FTIR) spectrometer and analyzed with 
OPUS  FTIR software was used to record the spectrum of 
pure SA nanocomposite beads, pure VPHCl drug, placebo 
and drug loaded nanocomposite beads to find out the 
possible chemical interactions between polymer and drug. 
Spectra were taken in the wavelength range 400-4000 cm-1.  
X-Ray Diffraction (XRD) Analysis 
Bruker D8 advanced refractometer X-ray diffraction (XRD) 
was used to determine pure VPHCl drug, drug loaded 
SA/PEO nanocomposite beads and MMT loaded 
SA/PEO/drug nanocomposite beads  were performed by a 
wide angle X-ray scattering diffractometer with CuKα 
radiation (λ= 1.54060) at a scanning rate of 5 °/min to 
determine the crystallinity. 
Field Emission Scanning Electron Microscopy (FESEM) 
Analysis 
The morphological characterization of the pure composite 
and drug, clay MMTloaded nanocomposite was observed by 
using Merlin Field Emission Scanning electron microscopy 
from Carl Zeiss (MODEL 1610-1217) with an accelerating 
voltage of 20 kV equipped with an EDAX detector.
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RESULTS AND DISCUSSIONS 
Fourier Transform Infrared (FTIR) Spectral Analysis 
 
Figure 2. FTIR spectra of pure sodium alginate (a), pure drug (b), pure clay MMT (c), drug loaded SA/PEO beads(d) and drug 
loaded SA/PEO/MMT nanocomposites beads 
 
The FTIR spectra of pure sodium alginate, VPHCl drug, MMT, 
drug loaded SA-PEO beads and drug loaded SA/PEO/MMT 
nanocomposite beads are shown in Figure 2. In the spectra of 
pure sodium alginate (a) the band at 3451 cm-1 corresponds 
to –OH stretching vibration. The peaks at 1627 and 1415 cm-
1 showed asymmetric and symmetric stretching vibrations of 
carboxyl anion and the band at 1045cm-1 is ether linkage C-O 
in cyclic bridge. The FTIR spectra of VPHCl (b), the 
absorption band at 2947cm-1showed the C-H stretching 
vibration of methoxy group, the peaks at 2785cm-1 is due to 
N-H stretching of the protonated amine group and a strong 
absorption band at 1260 cm-1 is C-O of aromatic ester group. 
In the FTIR spectrum of MMT (c) the peaks at 3450 and 3631 
cm-1 correspond to OH stretching mode in molecular water 
and in Si-OH, Al-OH bonds, respectively. The band at 1640 
cm-1 corresponds to the bending vibration of water; 1044, 
623 and 523 cm-1 are attributed to Si-O stretching in [SiO4]4- 
tetrahedral; 916 cm-1 is for Al-Al-OH bending vibration; 798 
cm-1 corresponds to Si-O vibration in SiO2 and 467 cm-1 to Si-
O-Si and Na-Al-OH vibrations. 
FTIR spectrum of verapamil hydrochloride loaded SA-PEO 
nanocomposite bead (d) resembled to the superimposition of 
the spectra corresponding to the drug and sodium alginate. 
This indicates that the interaction between the polymer 
matrix and drug is weak. The FTIR spectrum of MMT present 
SA/PEO/VPHCl nanocomposite revealed that the bands of 
the nanocomposite beads was  similar to alginate, which was 
major composition in the composite. The carboxyl and C-O 
(1685 and 1067 cm-1) stretching peaks of alginate decreased 
in intensity and shifted to a higher wave number. The 
negative charge of the carboxyl groups might have an 
electrostatic interaction with the positively charged sites 
which are present in the MMT33. The OH stretching peaks of 
alginate was shifted to a lower wave number (3401cm-1) in 
the MMT present nanocomposite. This indicates that the 
existence of intermolecular hydrogen bonding and 
electrostatic forces between drug, MMT and SA/PEO. 
 
X-ray Diffraction Analysis 
 
Figure 3. X-ray diffractograms of pure drug (a), drug loaded SA/PEO beads (d) and MMT loaded SA/PEO/drug nanocomposites 
beads 
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X-RD patterns of pure drug (a), drug loaded SA/PEO beads 
(b) and MMT loaded SA/PEO/drug nanocomposites beads 
are shown in Figure 3. The X-RD of plain drug has shown 
characteristic intense peaks at the 2theta in the range of 10-
250 which are characteristic of its crystalline nature. 
Whereas, in the case of drug loaded and MMT loaded 
nanocomposite beads, no intense peaks related to drug was 
observed. This indicates the molecular dispersion of the 
drug after incorporation into the nanocomposite beads.
 
 
FESEM and EDS Analysis 
 
Figure 4. FESEM images of plain sodium alginate (a), drug loaded SA/PEO beads(b), MMT loaded SA/PEO/drug beads(c,d) and 
EDS analysis of  drug loaded SA/PEO beads (e), MMT loaded SA/PEO/drug beads (f) 
 
FESEM and EDS images of the nanocomposite beads are 
shown in figure 4. As seen in the figure, the pure sodium 
alginate and drug loaded nanocomosite beads (a,b) shows 
smooth surface with detectable pores. Where as in the MMT 
loaded nanocomposite beads a rough surface was observed, 
it indicates that the polycation ability of the matrix was 
attracted to the negative ability of clay and resulted in a 
physical bond (hydrogen bond) form between them and it 
was also observed by Rhim et al.34 
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The presence of MMT in nanocomposite beads was 
confirmed by using EDS. The energy dispersive X-ray spectra 
of drug loaded SA/PEO(e) beads shows the presence of C, N, 
O,  Ca, Cl elements. These elements are present in the drug 
and in the polymers. Where as EDS shows  the presence of C, 
N, O, Ca, Cl, Al, Si elements in the MMT loaded SA/PEO/drug 
beads which confirms the presence of MMT in the 
nanocomposite beads.     
Encapsulation Efficiency 
The percentage of encapsulation efficiency values (%EE) of 
verapamil hydrochloride loaded nanocomposite beads are 
shown in Table.1. The values are lies between 57.25 to 76.17, 
this indicates that, the % of encapsulation efficiency depends 
on the percentage of blend composition, drug variation and 
amount of clay (MMT). The % of EE increases with increase 
of drug concentration of drug increases; this is due to as the 
concentration of drug increase, the amount of drug loaded in 
the matrix increases. The % of EE increases with increase the 
concentration of clay (MMT). This is due to the clay provides 
large area and good absorption capacity.    
In vitro drug release 
Drug-release kinetics was analyzed by plotting the 
cumulative release data versus time by fitting the data to a 
simple exponential equation 35 
(Mt/M∞) = ktn                               (3) 
 
Where Mt and M∞ represent the fractional drug release at 
time t, k is a constant characteristic of the drug-polymer 
system and n is an empirical parameter characterizing the 
release mechanism. Using the least square procedure, we 
have calculated the values of n and k for all the formulations 
and these values are given in Table-2.  If n= 0.5, the drug 
diffuses and release from the polymer matrix following a 
Fickian diffusion. For n > 0.5, anomalous or non-Fickian drug 
diffusion occurs. If n = 1, a completely non-Fickian or case-II 
release kinetics is operative. The intermediary values 
ranging between 0.5 and 1.0 are attributed to an anomalous 
type diffusive transport 35.   
In the present study, the values of k and n showed a 
dependence on the extent of PEO, drug loading and clay 
(MMT) content in nanocomposite beads. The values of n for 
beads prepared by using various amounts of VPHCl drug (50, 
70, 90 mg) while keeping blend composition and clay 
constant, ranged from 0.596 to 0.640 indicates Non-Fickian 
type. The clay (MMT) –loaded nanocomposite beads 
exhibited n values ranging from 0.596 to 0.721, indicating 
the Non- Fickian type mechanism. This may be due to the 
reduction in the regions of low microviscosity and closure of 
microcavities in the swollen state of the polymer. Similar 
findings have been observed elsewhere, where in the effect 
of different polymer ratios on dissolution kinetics was 
studied36.  Correlation coefficients, r2 obtained while fitting 
the release data are in the range from of 0.898 to 0.964.  
 
Table.2. Drug release rate constant and correlation coefficient of all formulations after fitting drug release data into 
mathematical model at pH-7.4. 








SPM-1 0.207 0.666 0.907 Non-Fickian 
SPM-2 0.298 0.608 0.898 Non-Fickian 
SPM-3 0.251 0.596 0.920 Non-Fickian 
SPM-4 0.225 0.626 0.937 Non-Fickian 
SPM-5 0.218 0.640 0.938 Non-Fickian 
SPM-6 0.208 0.721 0.928 Non-FIckian 
SPM-7 0.233 0.713 0.923 Non-Fickian 
SPM-8 0.082 0.707 0.902 Non-Fickian 
SPM-9 0.062 0.655 0.964 Non-Fickian 
 
 
Effect of drug variation 
Fig.5. shows the release profile of VPHCl loaded 
nanocomposite beads SPM-3, SPM-4 and SPM-5 at different 
amounts of drug loading (50, 70 and 90mg, respectively) in 
phosphate buffer solution pH-7.4(PBS) at 37oC. The release 
data shows that the nanocomposite beads containing higher 
amount of VPHCl drug (SPM-5) displayed faster and higher 
release rates than those formulations containing lower 
amount of VPHCl drug (SPM-3). A prolonged release was 
observed in the SPM-3 nanocomposite beads because it 
containing lower amount of drug. Notice that the release rate 
becomes quite slower at the lower amount of drug in the 
beads, due to the availability of more free void spaces 
through which a lesser no of drug molecules will transport 
 
Fig.5. % cumulative release of VPHCl drug through the 
nanocomposite beads containing different amounts of drug 
50mg (SPM-3), 70mg (SPM-4) and 90mg (SPM-5) at pH- 7.4. 
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Effect of MMT 
Figure 6. shows the effect of MMT on in vitro release studies 
was studied by plotting cumulative releases vs time at pH 
7.4. From 6. It is observed that the formulation (SPM-
3,40mg) which contain lower amount of MMT shows higher 
cumulative release and the formulation (SPM-7, 80mg) 
which contain higher amount MMT shows lower cumulative 
release. This is due to electrostatic and intermolecular 
hydrogen bonds formed between MMT, SA, PEO and drug.  It 
clearly explains that the MMT clay loaded formulations 
shows slower release rates of drug than compare with pure 
sodium alginate polymer. 
 
Fig.6. % cumulative release of VPHCl drug through the 
nanocomposite beads containing different amounts of MMT 
40mg (SPM-3), 60mg (SPM-6) and 80mg (SPM-7) at pH- 7.4. 
Effect of PEO 
To understand the release profiles of VPHCl from the 
nanocomposite beads SPM-3, SPM-8 and SPM-9 with 
different PEO concentrations (30, 40 and 50wt %) were 
studied in pH-7.4 at 37oC. From Fig.7; it was observed that 
the highest cumulative release is obtained in SPM-3 
formulation, which has lowest amount 30wt% of PEO. On the 
other hand, the least cumulative release was observed, the 
formulation containing higher amount (50wt %) of PEO. 
When the amount of PEO increased in the nanocomposites 
beads, the drug release was decreased and a lower 
cumulative release was observed for the formulation 
containing higher amount of PEO. It may be due to 
developing of hydrogen bonding between –OH group of 
sodium alginate and oxygen atom of PEO.  
 
Fig.7. % cumulative release of VPHCl drug through the 
nanocomposite beads containing different amounts of PEO 
30wt% (SPM-3), 40wt% (SPM-8) and 50wt% (SPM-9) at pH- 
7.4. 
CONCLUSIONS 
VPHCl drug incorporated nanocomposite beads based on 
Sodium Alginate/Polyethylene oxide/Montmorillonite were 
prepared by ionotropic gelation technique. The FTIR 
spectroscopy revealed the existence of intermolecular 
hydrogen bonding between MMT,drug-polymer. The X-RD 
data indicates the molecular dispersion of drug into 
nanocomposite. EDS confirms the presence of MMT into 
nanocomposite beads. The in vitro drug release studies 
clearly suggested pure sodium alginate is hydrophilic in 
nature it shows burst relase, whereas MMT nanoclay loaded 
polymeric matrice provides new insight into inter layer 
structure, the drug molecules present in the interlayer 
structure and comes out slowly from the beads. The results 
of controlled release tests showed that the amount of VPHCl 
release decreased with an increase of PEO and increase of 
MMT, the amount of drug release increased with increase of 
drug amount. By observing all the results the MMT loaded 
nanocomposite beads was a quite promising for controlled 
release of VPHCl drug. The prolonged release rates of VPHCl 
were observed upto 12h.  
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